China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010
  • Feb/2011
  • Hard Copy
  • USD $2,100
  • Pages:80
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: JMH005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,300
      
In 2009, the consumption of oral hypoglyceimic agents (OHAs) in China increased by 15.1% to RMB9.81 billion, accounting for approximately 5% of the world’s total. At present, China is a country with the most populous victims of diabetes, numbering as high as 92 million. But the treatment rate of this disease in China is, generally speaking, less than 30%. Coupled with the comparatively low per capita treatment payment, which is no more than 3% of that in the US, China will witness a huge potential in the OHAS market.     

Among all the OHAS, patent medicines made by overseas pharmaceutical enterprises are hailed as “star products”. Many generic drugs exert little impact on patent medicines although they spring up. Meanwhile, foreign enterprises firmly control Chinese market by means of successful marketing strategy and product upgrading. In 2009, foreign enterprises occupied the top 5 by procurement value among the OHAS providers for China-based hospitals, making up as high as 60.8%. In particular, the ranking first Bayer, an acarbose producer, enjoyed a share of 29.4%. Of the top 10 enterprises by sales performance, Beijing Wanhui Double-Crane Pharmaceutical was the sole homegrown enterprise that produces gliquidone, with the market share no more than 3.7%.

Leading Enterprises and Market Share of OHAS Providers for China-based Hospitals, 2009
 
2011022501.gif
 
Source: China Pharmaceutical Industry Association; ResearchInChina

The report not only probes into the status quo and competition pattern of the market, drug use of hospitals, and development tendency of OHAS industry, but also analytically elaborates the market segments as well as the operation and prospect of leading manufacturers, including 7 foreign enterprises and joint ventures playing dominant position in OHAS traditional western medicine varieties and Chinese patent medicine market as well as four Chinese counterparts of certain scale.

 
OHAS Products Made in China and Market Share of Preventative Manufacturers in Hospital Medicine Market, 2009
2011022502.gif
Source: ResearchInChina

In addition, new OHAS varieties such as DDP-IV inhibitor and GLP-1 analog have been inflowing into Chinese market, including Januvia produced by Merck & Co Inc, and Onglyza by Bristol-Myers Squibb and AstraZeneca, which pose grave threat to traditional OHAS because of the good effect and little side-effect.

1. Overview of OHAS Industry
1.1 Definition
1.2 Classification

2. Status Quo and Prospect of Chinese OHAS Market
2.1 Status Quo of International Market
2.1.1 Market Size
2.1.2 Demand and Supply
2.2 Status Quo of Chinese Market
2.2.1 Market Size
2.2.2 Product Mix
2.3 Demand and Supply
2.4 Competition Pattern
2.5 Gross Margin of the Industry and Prices
2.6 Application of OHAS in Key Cities
2.6.1 Beijing
2.6.2 Shanghai
2.6.3 Guangzhou
2.6.4 Shenzhen
2.7 Policy Environment
2.8 Development Outlook
2.8.1 Huge Diabetic Population 
2.8.2 Improvement in Treatment Rate and Expense of Diabetic Patients
2.8.3 Strong Growth of New OHAS Varieties

3. Key Varieties of OHAS
3.1 Acarbose
3.2 Metformin
3.3 Repaglinide
3.4 Glimepiride
3.5 Gliclazide
3.6 Glipizide
3.7 Gliquidone
3.8 Rosiglitazone
3.9 DDP-IV Inhibitor 
3.10 GLP-1 Analog 

4. Advantageous Foreign Enterprises in China OHAS Industry
4.1 Bayer
4.1.1 Profile
4.1.2 Operation
4.1.3 Operation in China
4.2 Bristol-Myers Squibb
4.2.1 Profile
4.2.2 Operation
4.2.3 Shanghai Bristol-Myers Squibb
4.2.4 Developments
4.3 Novonordisk
4.3.1 Profile
4.3.2 Operation
4.3.3 Operation in China
4.3.4 Developments
4.4 Sanofi-Aventis
4.4.1 Profile
4.4.2 Operation
4.4.3 Operation in China
4.5 Servier
4.5.1 Profile
4.5.2 Servier (Tianjin) Pharmaceutical
4.6 Pfizer
4.6.1 Profile
4.6.2 Operation in China
4.7 GlaxoSmithKline
4.7.1 Profile
4.7.2 Operation
4.7.3 Operation in China

5. Local Advantageous Enterprises in China OHAS Industry
5.1 Huadong Medicine
5.1.1 Profile
5.1.2 Operation
5.1.3 Developments
5.2 Wanbang Biopharmaceuticals
5.2.1 Profile
5.2.2 Operation
5.3 Double-Crane Pharmaceutical
5.3.1 Profile
5.3.2 Operation
5.3.3 Developments
5.4 Guangzhou Pharmaceutical
5.4.1 Profile
5.4.2 Operation
Diabetes Types
Subdivided Varieties and Products of OHAS
Sales Value and YOY Growth of Anti-Diabetic Agents Worldwide, 2005-2009
Classification and Proportion of Anti-Diabetic Agents Worldwide, 2010
Population of Diabetic Suffers Worldwide, 2005-2009
Top 3 Countries with the Most Diabetic Victims, 2009
Consumption and Growth Rate of OHAS in China, 2007-2009
Ranking of Chinese Sample Hospitals by Purchasing Sum of OHAS Varieties, 2008 
Ranking of Chinese Sample Hospitals by Purchasing Sum of Leading OHAS Varieties, 2009
Ranking of Chinese Sample Hospitals by Import Value of Imported OHAS, 2009
Competitors and Proportion on OHAS Use Market of Chinese Sample Hospitals, 2009
OHAS Gross Margin of Partial Enterprises in China, 2009-2010
Prices of Partial OHAS Products of Golden Elephant Pharmacy, Feb. 2011
Ranking of Beijing Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
Varieties and Proportion of OHAS Used by Beijing Community Health Service Agency, 2009H1
Ranking of Shanghai Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
Ranking of Guangzhou Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
OHAS Retail Market Scale in Shenzhen, 2008-2009H2
Proportion of OHAS Retail Market by Subclass in Shenzhen, 2009H2
Proportion of Various Enterprises in Shenzhen OHAS Retail Market, 2009H2
OHAS being Included in Catalogue of National Essential Drugs (2009)
OHAS being Included in Catalogue of National Basic Medical Insurance and Employment Injuries Insurance Drugs (2009) 
Diabetes Morbidity in China, 1980-2008
Average Treatment Expense of Diabetic Sufferers in China, 2009
OHAS Products and Representative Enterprises in China
Major Enterprises and Their Shares in China’s Acarbose Market, 2009 
Major Acarbose API & Preparation Manufacturers and Their Output, 2009
Competitors in China’s Voglibose Market and Market Shares, 2009
Competitors and Market Shares as Metformin Providers for China’s Leading Hospitals, 2009
Metformin API Producers and Their Output, 2009
Metformin Preparation Producers and Their Outputs, 2009
Imported & Homemade Repaglinide Purchased by China’s Sample Hospitals by Sum & Proportion, 2009
Major Enterprises and Proportion in Repaglinide Market, 2009
Imported & Homemade Glimepiride Purchased by China’s Sample Hospitals by Sum & Proportion, 2009
Major Enterprises and Proportion in Glimepiride Market, 2009
Glimepiride API Producers and Their Outputs in China, 2009
Competitors and Market Shares as Gliclazide Providers for China’s Leading Hospitals, 2009
Gliclazide Preparation Producers and Their Output, 2009
Hospitals’ Purchasing Sum of Glipizide/Melbine/Glibenclamide, 2005-2008
Competitors and Market Shares as Glipizide Providers for China’s Leading Hospitals, 2009
Glipizide Preparation Producers and Their Output, 2009
Major Enterprises and Proportion in Gliquidone Market of China, 2009
Gliquidone API & Preparation Producers and Their Output, 2009
Global Sales Value of Gliquidone Drugs, 2005-2009
Competitors and Market Shares as Gliquidone Providers for China’s Leading Hospitals, 2009
Pioglitazone Preparation Producers and Their Output, 2009
Sales Revenue of Januvia Worldwide, 2006-2009
Sales Revenue of Onglyza Produced by Shanghai Bristol-Myers Squibb, 2009-2010
Major DDP-IV Inhibitor Drugs Going Public
Leading GLP-1 Analogues 
Organization Structure of Bayer HealthCare AG
Global Sales Value of Bayer HealthCare Group, 2007-2010
Top 10 Products of Bayer Pharmaceuticals Division, Jan.-Sep., 2010
Global Sales Value and YoY Growth of Glucobay Produced by Bayer HealthCare AG, 2007-2010
Subsidiaries of Bayer HealthCare AG in China, as of 2009
Sales Value of Glucobay Produced by Bayer HealthCare AG in China, 2008-2009
Sales Value and YoY Growth of Bristol-Myers Squibb, 2007-2010
Sales Revenue Structure of Bristol-Myers Squibb, Jan.-Sep., 2010
Sales Revenue of Major Products Made by Bristol-Myers Squibb, 2007-2009  
Global Sales Revenue of Glucophage Made by Bristol-Myers Squibb, 2007-2008
Product Category of Bristol-Myers Squibb
Market Share of Glucophage Made by Shanghai Squibb Pharmaceuticals in China Melbine Market, 2008-2009
Dosage Form and Output of OHAS Preparation Made by Shanghai Squibb Pharmaceuticals, 2009
Dynamics in OHAS Field of Shanghai Squibb Pharmaceuticals, 2010
Primary Businesses and Products of Novonordisk, 2010H1
OHAS Products of Novonordisk, 2010
Operating Income and Net Income of Novonordisk, 2008-2010
Operating Income Structure of Diabetes Therapy Department of Novonordisk, Jan.-Sep., 2010
OHAS Sales Revenue and YoY Growth of Novonordisk in the World, 2007-2010 
Operating Income of Victoza Made by Novonordisk, 2010Q1-Q3
China-based Companies of Novonordisk and Their Businesses, 2009  
Sales Revenue and Market Share of Novonordisk-Made Repaglinide in China’s Sample Hospitals 
Key Developments of Novonordisk, 2010-2011
Diabetes Products of Sanofi-Aventis, 2009
Operating Income and Profit of Sanofi-Aventis, 2007-2010
Operating Income and YoY Growth of Glimepiride Produced by Sanofi-Aventis, 2007-2010
Glimepiride Operating Income of Sanofi-Aventis by Region, Jan.-Sep., 2010   
China-Based Companies under Sanofi-Aventis, 2010
Sales Revenue of Glimepiride in China’s Sample Hospitals and Market Share in Glilmepiride Market, 2008-2009
New Plants of Sanofi-Aventis Under Construction, as of 2010
Total Sales of Servier, 2009-2010
Registered Products Going Public in China of Servier
Market Share of Gliclazide Made by Servier (Tianjin) in China’s Sample Hospitals, 2008-2009
Businesses of Pfizer
Global Operating Income of Pfizer by Sector, 2007-2010
China-Based Manufacturers under Pfizer
Market Share of Glipizide Controlled-Rrelease Tablets Made by Pfizer in China’s Sample Hospitals, 2008-2009
Key Prescription Medicines and Treatment Fields of GlaxoSmithKline
Operating Income and Profit of GlaxoSmithKline, 2007-2010
Sales Revenue and YoY Growth of Avandia Products Made by GlaxoSmithKline, 2007-2010
Sales Revenue and YoY Growth of Avandia Products Made by GlaxoSmithKline, 2010Q1-Q3
China-Based Operating Companies under GlaxoSmithKline, as of 2010  
Sales Revenue and Market Share of Rosiglitazone Products Made by GlaxoSmithKline in China’s Sample Hospitals, 2008-2009
OHAS Products of Huadong Medicine
Operating Income and Total Profit of Huadong Medicine, 2007-2010
Operating Income and Net Income of Hangzhou Sino-US Huadong Medicines Group
Operating Income and Proportion of Acarbose Tablets & Pioglitazone Hydrochloride Tablets Made by Sino-US Huadong Medicines Group, 2009
Output and Export Volume of OHAS API Made by Sino-US Huadong Medicines Group, 2009
Dosage Form and Output of OHAS Preparation Made by Sino-US Huadong Medicines Group, 2009
Dynamics in Key Anti-Diabetes Agents Industry of Huadong Medicine, 2009-2010
Information about Jiangsu Wanbang Bio-pharm
Net Income of Primary Businesses of Jiangsu Wanbang Bio-pharm, 2007-2010
Sales Revenue and Market Share of Glimepiride Tablets in China’s Sample Hospitals, 2008-2009
Three Leading Medicines of Double-Crane Pharmaceutical
OHAS Products of Double-Crane Pharmaceutical, as of 2010
Operating Income and Total Profit of Double-Crane Pharmaceutical, 2007-2010
Sales Revenue of 3 Leading Products and Proportion in Operating Income of Double-Crane Pharmaceutical, 2009
Sales Revenue of Gliquidone Made by Double-Crane Pharmaceutical, 2008-2010
Dosage Form and Output of OHAS Preparation Made by Double-Crane Pharmaceutical, 2009
Major Chinese Patent Medicines and Treatment Fields of Guangzhou Pharmaceutical
Operating Income and Total Profit of Guangzhou Pharmaceutical, 2008-2010
Sales Value of Thirsty Releever Made by Guangzhou Pharmaceutical, 2007-2010

China Dental Industry Report, 2014-2018

Oral industry refers to the medical industry chain on the basis of oral medical consumption, mainly covering oral medical apparatus (equipment and consumables) and oral medical services. As reform of ...

China Medical Monitor Industry Report, 2014-2017

With advancement of medical reform, improvement of spending power, and enhancement of health care consciousness, China’s medical monitor industry is gradually expanding. During 2007-2013, the market s...

China Independent Clinical Laboratory Industry Report, 2014-2017

The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there...

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统